Orthofix International NV (NASDAQ:OFIX) saw unusually-strong trading volume on Wednesday . Approximately 328,557 shares were traded during mid-day trading, an increase of 163% from the previous session’s volume of 124,703 shares.The stock last traded at $42.23 and had previously closed at $42.48.

A number of equities analysts recently weighed in on OFIX shares. Zacks Investment Research downgraded shares of Orthofix International NV from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 4th. TheStreet raised shares of Orthofix International NV from a “hold” rating to a “buy” rating in a report on Monday, May 2nd.

The firm has a 50-day moving average price of $45.36 and a 200 day moving average price of $42.38. The company has a market cap of $769.85 million and a P/E ratio of 83.62.

Orthofix International NV (NASDAQ:OFIX) last announced its quarterly earnings results on Monday, August 1st. The medical device company reported $0.41 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.08. The business earned $104.10 million during the quarter, compared to analysts’ expectations of $102.40 million. The business’s revenue was up 3.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.36 EPS. On average, analysts predict that Orthofix International NV will post $1.36 earnings per share for the current fiscal year.

In other Orthofix International NV news, CEO Brad Mason sold 18,336 shares of the firm’s stock in a transaction on Thursday, June 9th. The stock was sold at an average price of $46.00, for a total transaction of $843,456.00. Following the completion of the transaction, the chief executive officer now owns 160,256 shares of the company’s stock, valued at $7,371,776. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Maria Sainz sold 4,157 shares of the firm’s stock in a transaction on Friday, June 10th. The shares were sold at an average price of $46.33, for a total value of $192,593.81. Following the transaction, the director now directly owns 20,828 shares of the company’s stock, valued at approximately $964,961.24. The disclosure for this sale can be found here.

A number of institutional investors have recently made changes to their positions in OFIX. GSA Capital Partners LLP raised its position in shares of Orthofix International NV by 18.3% in the fourth quarter. GSA Capital Partners LLP now owns 42,609 shares of the medical device company’s stock valued at $1,671,000 after buying an additional 6,601 shares in the last quarter. Diamond Hill Capital Management Inc. raised its position in shares of Orthofix International NV by 5.6% in the fourth quarter. Diamond Hill Capital Management Inc. now owns 861,860 shares of the medical device company’s stock valued at $33,794,000 after buying an additional 45,984 shares in the last quarter. Russell Frank Co raised its position in shares of Orthofix International NV by 80.3% in the fourth quarter. Russell Frank Co now owns 43,978 shares of the medical device company’s stock valued at $1,741,000 after buying an additional 19,582 shares in the last quarter. Marshall Wace LLP purchased a new position in shares of Orthofix International NV during the fourth quarter valued at approximately $1,443,000. Finally, California State Teachers Retirement System raised its position in shares of Orthofix International NV by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 34,774 shares of the medical device company’s stock valued at $1,363,000 after buying an additional 600 shares in the last quarter.

Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.